Pegavision Corporation (TPE: 6491)
Taiwan
· Delayed Price · Currency is TWD 384.00
+4.00 (1.05%)
Jan 3, 2025, 1:30 PM CST
Pegavision Revenue
Pegavision had revenue of 1.66B TWD in the quarter ending September 30, 2024, a decrease of -1.08%. This brings the company's revenue in the last twelve months to 7.06B, up 8.15% year-over-year. In the year 2023, Pegavision had annual revenue of 6.79B with 7.41% growth.
Revenue (ttm)
7.06B
Revenue Growth
+8.15%
P/S Ratio
4.24
Revenue / Employee
n/a
Employees
n/a
Market Cap
29.95B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 6.79B | 468.66M | 7.41% |
| Dec 31, 2022 | 6.32B | 726.16M | 12.98% |
| Dec 31, 2021 | 5.60B | 1.62B | 40.64% |
| Dec 31, 2020 | 3.98B | 623.28M | 18.58% |
| Dec 31, 2019 | 3.36B | 222.46M | 7.10% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 8.32B |
| Caliway Biopharmaceuticals | 49.98M |
| Lotus Pharmaceutical | 17.59B |
| Oneness Biotech | 112.20M |
| Lumosa Therapeutics | 37.82M |
| Polaris Group | 75.65M |
| Center Laboratories | 1.57B |
| TaiMed Biologics | 622.61M |